Neuro · Vol. 3, No. 1 · 2016 · pp. 13–17 · e-ISSN 2377-1607

Neuromodulation and Non-Pharmacological Treatment of Migraine

Mohtashem Samsam

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida 4364 Scorpius St., HPA-II, 320, Orlando, FL 32816, USAUnited States

DOI: https://doi.org/10.17140/noj-3-e006 · Published 2016-12-30 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2016 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Migraine is a chronic brain disorder that is believed to be due to dysfunction of the brain and brainstem that result in dysmodulation of sensory processing of the head and vascular tone. The exact pathomechanism of migraine is not known but some genes including mutations in the sodium and calcium channels and Na+ /K+ pump have been implicated in migraine with aura.1-8 Several drugs are currently used in the acute and preventive treatment of migraine. These include the non-steroidal anti-inflammatory drugs, the triptan family, anti-epileptic drugs, beta-blockers, calcium channel blockers, steroids, and recently antibodies against calcitonin gene-related peptide (CGRP) or its receptor among other drugs.5,9 Some other drugs are under investigation and the CGRP receptor antagonists (the gepant family drugs), were discontinued although other drugs in this category are still under investigation.10-16 However, there are some medically intractable headaches or unsatisfactory patient managemen

Keywords: receptor; unsatisfactory

Acknowledgments

This work has been supported by internal funding by the Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA.

Conflicts Of Interest

There is no conflicts of interest.

References

  1. WeillerCMayALimmrothV. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1: 658-660. doi: 10.1038/nm0795-65810.1038/nm0795-658 https://doi.org/10.1038/nm0795-658
  2. GoadsbyPJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007; 13(1): 39-44. doi: 10.1016/j.molmed.2006.11.00510.1016/j.molmed.2006.11.005 https://doi.org/10.1016/j.molmed.2006.11.005
  3. AkermanSHollandPRGoadsbyPJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-84. doi: 10.1038/nrn305710.1038/nrn3057 https://doi.org/10.1038/nrn3057
  4. SamsamM. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem. 2012; 12(3): 158-172. doi: 10.2174/18715241280243014710.2174/187152412802430147 https://doi.org/10.2174/187152412802430147
  5. SamsamM. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: What are the new progresses? Neuro Open J. 2015; 2: 79-91. doi: 10.17140/NOJ-2-11710.17140/noj-2-117 https://doi.org/10.17140/noj-2-117
  6. LauritzenM. Pathophysiology of the migraine aura: The spreading depression theory. Brain. 1994; 117 (Pt 1): 199-210. doi: 10.1093/brain/118.1.30710.1093/brain/118.1.307 https://doi.org/10.1093/brain/118.1.307
  7. Tfelt-HansenPC. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia. 2010; 30(7): 780-792. doi: 10.1111/j.1468-2982.2009.02015.x10.1111/j.1468-2982.2009.02015.x https://doi.org/10.1111/j.1468-2982.2009.02015.x
  8. Lauritzen M, Strong AJ. ‘Spreading depression of Leão’ and its emerging relevance to acute brain injury in humans. J Cereb Blood Flow Metab. 2016; pii: 0271678X16657092. doi: 10.1177/0271678X16657092 https://doi.org/10.1177/0271678x16657092
  9. EversSAfraJFreseA. EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur Neurol. 2009; 16(9): 968-981. doi: 10.1111/j.1468-1331.2009.02748.x10.1111/j.1468-1331.2009.02748.x https://doi.org/10.1111/j.1468-1331.2009.02748.x
  10. DodickDWGoadsbyPJSpieringsEL. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin generelated peptide, for the prevention of migraine:A phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13(9): 885-892. doi: 10.1016/S1474-4422(14)70128-010.1016/s1474-4422(14)70128-0 https://doi.org/10.1016/s1474-4422(14)70128-0
  11. DodickDWGoadsbyPJSilbersteinSD. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomized, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-110.1016/s1474-4422(14)70209-1 https://doi.org/10.1016/s1474-4422(14)70209-1
  12. BigalMEEscandonRBronsonM. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Cephalalgia. 2013; 34(7): 483-492. doi: 10.1177/033310241351777510.1177/0333102413517775 https://doi.org/10.1177/0333102413517775
  13. BigalMEDodickDWKrymchantowskiAV. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at J NEURO early time points. Neurology. 2016; 87(1): 41-48. doi: 10.1212/WNL.000000000000280110.1212/wnl.0000000000002801 https://doi.org/10.1212/wnl.0000000000002801